• 1
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1998; 337: 102935.
  • 2
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398405.
  • 3
    Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999; 116: 228.
  • 4
    Plevy SE, Landers CJ, Prehn J, et al. A role for TNFα mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 1997; 159: 627682.
  • 5
    D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999; 116: 102934.
  • 6
    Pasparakis M, Alexopoulou L, Grell M, et al. Peyer’s patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc Natl Acad Sci USA 1997; 94(12): 631923.DOI: 10.1073/pnas.94.12.6319
  • 7
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 7619.
  • 8
    Wagner C, Mace K, DeWoody K, et al. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn’s disease patients. Digestion 1998; 59(Suppl. 3): 1245.
  • 9
    Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The US Simulect Renal Transplant Study Group. Transplantation 1999; 68(9): 128894.
  • 10
    Scallon BJ, Arevalo Moore M, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 1995; 7: 2519.DOI: 10.1006/cyto.1995.0029
  • 11
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. N Engl J Med 1980; 302: 9817.
  • 12
    Maurice MM, Van Der Graaf WL, Leow A, Breedveld FC, Van Lier RA, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 216673.
  • 13
    O'Donoghue DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978; 4 November; 9557.
  • 14
    Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 74960.